GILEAD SCIENCES, INC. Decrease in Unrecognized Tax Benefits is Reasonably Possible
GILEAD SCIENCES, INC. (GILD) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $100.00 million as of 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2022-02-23
- 2021-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $100.00M.
- 2020-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $500.00M.
- 2020-03-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $500.00M.
- 2018-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $100.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2021-12-31 | $100.00M 10-K · filed 2022-02-23 |
| 2020-06-30 | $500.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $500.00M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $100.00M 10-K · filed 2019-02-26 |
| 2018-09-30 | $100.00M 10-Q · filed 2018-11-06 |
| 2018-03-31 | $800.00M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $800.00M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |